Thermo Fisher to accelerate commercialization for gene, cell therapy

30 May 2019 | News

New collaboration will enable scalable, cost-effective manufacturing processes

image credit-

image credit-

Thermo Fisher Scientific, the world leader in serving science, has announced a collaboration with Scinogy, specialists in closed, automated manufacturing systems for cell therapies, to develop and commercialize fit-for-purpose instrumentation and reagent systems aimed at improving productivity and scalability of cell and gene therapy manufacturing.

The manual processes commonly used in development and clinical trials are not cost-effective, transferable, or commercially viable.  Alternative methods using more integrated systems often lack flexibility and generally suffer from poor capacity utilization. To realize the promise of cell therapy, the industry requires a novel approach. Thermo Fisher's collaboration with Scinogy will provide closed, modular, automated systems designed to enable scalable, cost-effective cell and gene therapy development and manufacturing.

As an initial result of the collaboration, Thermo Fisher will unveil the new Gibco CTS Rotea Counterflow Centrifugation System at the International Society for Cellular Therapy meeting in Melbourne from May 29-June 1. The Rotea counterflow centrifuge is a highly reproducible, closed cell processing system designed for separation, washing and concentration of both autologous and small-scale allogeneic cell therapy samples.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account